OPKO Health, Inc. (NASDAQ:OPK), today announces
that GeneDx, a subsidiary of OPKO Health, is proud to participate
as a founding member in Illumina Inc.’s (NASDAQ:ILMN) iHope Network
on International Rare Disease Day, which takes place today.
iHope Network is led by a group of clinical laboratory
partners committed to providing clinical whole-genome sequencing
(cWGS) to children with undiagnosed rare diseases. The iHope
program aims to offer this advanced technology to help end
diagnostic odysseys that these patients and their families endure.
In addition to GeneDx, the iHope Network currently consists of the
following institutions: Illumina, the Garvan Institute of Medical
Research, and Hudson Alpha.
As an iHope Network partner, GeneDx has committed to donating 10
whole-genome sequencing tests per year. The variants identified
through testing will be shared via public variant databases
including ClinVar. By sharing this variant information, GeneDx
continues its long-standing commitment to sharing data for better
patient care while also contributing to the rare disorder community
through further collaboration and research.
“We are thrilled to have GeneDx as a founding member of the
iHope Network, which will transform the lives of pediatric patients
with limited access to resources and who need a genetic diagnosis
quickly. As a leader in the field, GeneDx’s clinical whole-genome
testing will prove invaluable to these families,” said Ryan Taft,
PhD, Senior Director of the Scientific Research Population and
Medical Genomics Department, Illumina.
GeneDx was founded in 2000 by two scientists from the National
Institutes of Health (NIH) with a mission to provide diagnostic
testing for patients with rare and ultra-rare disorders. Today,
GeneDx has grown into a global industry leader in genomics, having
provided testing to patients and their families in over 55
countries. Led by its world-renowned whole exome sequencing
program, and an unparalleled comprehensive genetic testing menu,
GeneDx has a continued expertise in rare disorders. Both GeneDx and
the iHope program strive to provide answers to those affected by
rare diseases and to increase awareness for these disorders.
“We are delighted to become a participating partner of
Illumina’s iHope Network,” said Jane Juusola, PhD, FACMG, Director
of the Clinical Genomics Program, GeneDx. “As a laboratory founded
to address the needs of patients diagnosed with rare genetic
diseases, the very principle of the iHope program aligns with our
founding mission. Through our donation of 10 whole-genome
sequencing tests, we hope to bring closure to the diagnostic
odysseys for children with undiagnosed rare diseases.”
About GeneDx
GeneDx is a world leader in genomics with an acknowledged
expertise in rare and ultra-rare genetic disorders, as well as one
of the broadest menus of sequencing services available among
commercial laboratories. GeneDx provides testing to patients and
their families in more than 55 countries. GeneDx is a
business unit of BioReference Laboratories, a wholly owned
subsidiary of OPKO Health, Inc. To learn more, please visit
www.genedx.com.
For GeneDx’s complete list of testing options, please visit
www.genedx.com or email genedx@genedx.com. Follow on Twitter
@GeneDx and become a fan on Facebook @GeneDxLab to get real-time
updates.
About OPKO Health
OPKO Health is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing
markets. Our diagnostics business includes BioReference
Laboratories, the nation’s third-largest clinical laboratory with a
core genetic testing business and a 400-person sales and marketing
team to drive growth and leverage new products, including the
4Kscore® prostate cancer test and the Claros® 1 in-office
immunoassay platform. Our pharmaceutical business features
RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD
patients with vitamin D insufficiency (launched in November 2016),
VARUBI™ for chemotherapy-induced nausea and vomiting (oral
formulation launched by partner TESARO and IV formulation pending
FDA approval), TT401, a once or twice weekly oxyntomodulin for type
2 diabetes and obesity which is a clinically advanced drug
candidate among the new class of GLP-1 glucagon receptor dual
agonists, and TT701, an androgen receptor modulator for androgen
deficiency indications. Our biologics business includes hGH-CTP, a
once weekly human growth hormone injection (in Phase 3 and
partnered with Pfizer), a long-acting oxyntomodulin for diabetes
and obesity (in Phase 1). We also have production and distribution
assets worldwide, multiple strategic investments and an active
business development strategy. More information available at
www.opko.com.
SAFE HARBOR STATEMENT
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), and such statements may be identified by
words such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding
expected benefits of the iHope program, that it will benefit
patients with rare disease and better patient care, as well as
other non-historical statements about our expectations, beliefs or
intentions regarding our business, technologies and products,
financial condition, strategies or prospects. Many factors could
cause our actual activities or results to differ materially from
the activities and results anticipated in forward-looking
statements. These factors include those described in our filings
with the Securities and Exchange Commission, as well as the risks
inherent in funding, developing and obtaining regulatory approvals
of new, commercially-viable and competitive products and
treatments. In addition, forward-looking statements may also be
adversely affected by general market factors, competitive product
development, product availability, federal and state regulations
and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions
and litigation, among other factors. The forward-looking statements
contained in this press release speak only as of the date the
statements were made, and we do not undertake any obligation to
update forward-looking statements. We intend that all
forward-looking statements be subject to the safe-harbor provisions
of the PSLRA.
Contacts:
OPKO Health, Inc.David Malina,
305-575-4137dmalina@opko.comInvestor Relations
Or
GeneDxHarpreet Somal, 201-937-9496harpreet@genedx.com
Media
Rooney & AssociatesTerry Rooney,
212-223-0689trooney@rooneyco.com
Or
Marion Janic, 212-223-4017mjanic@rooneyco.com
Or
InvestorsLHAAnn Marie Fields, 212-838-3777afields@lhai.com
Or
Bruce Voss, 310-691-7100bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024